Direct and Indirect Drug Design Approaches for the Development of Novel Tricyclic Antipsychotics: Potential 5‐HT 2A Antagonist

Schizophrenia is a mental disorder manifested largely by disintegration of thought processes and emotional responsiveness. Given the therapeutic and toxic limitations of clinically available drugs, it is clear that there is still a need for the development of new generation antipsychotic agents with an improved clinical profile. Development of novel hybrid atypical tricyclic antipsychotic pharmacophore was achieved using direct (by measuring docking score of designed molecules on modelled 5‐HT 2A receptor) and indirect (current, clinically available therapeutic agents’ data) drug design approaches.